Podcasts about ADT

Alexis Fink joined us on The Modern People Leader. We talked about how AI is changing work, why org design needs to move beyond boxes and lines, and how curiosity, influence, courage, and better systems thinking can help people leaders design for the future.----  Sponsor Links:

What if one of the hardest parts of androgen deprivation therapy is not simply low testosterone—but the loss of estradiol that comes with it?Dr. Richard Wassersug brings a rare dual perspective to that question.He is a PhD evolutionary biologist, former professor of anatomy and neurobiology, prostate cancer quality-of-life researcher, co-developer of an androgen deprivation education program, and a patient who has used transdermal estradiol for more than two decades. His experience helped drive a deeper investigation into whether estrogen delivered through the skin could suppress testosterone while avoiding some of the burdens associated with standard LHRH-based ADT.In this episode, you'll learn:

Dean Carter (Best-Selling Author, 4x CHRO, & CEO of Instill)  joined us on The Modern People Leader. We talked about the career pivots that shaped his life, what Patagonia taught him about purpose and play, and why trusting your gut, taking big swings, and doing the right thing can lead you somewhere better than the plan you originally had.----  Sponsor Links:

What happens when a graphic designer decides to document his own cancer diagnosis in a comic, panel by panel?Georgia-based artist and prostate cancer education advocate James Burns joins Leah to talk about his autobiographical medical graphic novels “The Death of Me” and “The Half-Life,” which chronicle his stage 4A prostate cancer diagnosis, treatment, and life after.James shares why he posted his diagnosis publicly on Instagram and how he pushes back on the expectation that men need to stay stoic through illness. He talks about his earlier comics that documented the time he had treatment for detached retinas, losing his voice following thyroid surgery, and a fall that lead to a completely unrelated surgery. He also gives specifics of this diagnosis and treatment, from an elevated PSA to MRIs, biopsy, and PMSA PET scans to 28 fractions of radiation therapy. James talks candidly about ADT side effects including brain fog and hot flashes, and how he uses exercise and weightlifting to combat the muscle loss from taking hormone blocking medication. Head to his website https://burnscomics.com/ to download PDFs of his comics.Follow him on Instagram: https://www.instagram.com/jpburnsand on BlueSky: https://bsky.app/profile/jpburns.bsky.socialSeptember is Prostate Cancer Awareness Month. Learn more about prostate cancer at malecare.orgLeave a message and let us know what you liked about the episode!Support the showBecome a member of The Cancer Pod Community! Support the podcast and gain access to exclusive content and more! Join today on Buy Me a Coffee or Patreon.Check out thecancerpod.com! Looking for more information? The website has blogs, merch, and all of the episodes listed by season and category. Shop the Bookshop! The shelves at Bookshop feature books by authors who have been on the show and other fav books.Buy The Cancer Pod merch! Whether it's a cozy hoody or a handy water bottle, we have something for everybody.Have a comment or suggestion? Email info (at) thecancerpod (dot) com Follow @TheCancerPod on social media:InstagramBlueskyFacebookLinkedInYouTube

D.V. Williams, Chief People Officer from Match Group joined us on The Modern People Leader. We talked about why Match is betting on Gen Z talent, how skills are replacing titles as the new currency of work, and how Match is thinking about flexible mentorship and early-career programs.----  Sponsor Links:

Christy Lake, Chief Administrative Officer at Twilio, joined us on The Modern People Leader. We talked about how AI is changing work, why skills, governance, and human judgment matter more than ever, and how Twilio is thinking about remote-first work, employee experience, and curiosity in the AI era.----  Sponsor Links:

Episode Overview:  In this episode of The Penis Project Podcast, Melissa sits down with Will McDonald, Channel 9 news reporter, PCFA ambassador, Ironman finisher, skydiver and father, for a candid and inspiring conversation.    Will was 42 when he was diagnosed with stage 4 prostate cancer that had metastasised to his hip. He was fit, active and had no urinary symptoms whatsoever. The first sign anything was wrong was a nagging pain in his left hip that simply never got better. Six weeks later an MRI revealed lesions that were almost certainly cancerous, and his PSA, when it was finally tested, confirmed prostate cancer as the source.  What followed was hormone therapy, chemotherapy, radiation to his prostate, lymph nodes and hip, and the beginning of a very different kind of life. Six years on, Will's PSA remains undetectable. He is still on androgen deprivation therapy, taking medication twice daily alongside a three-monthly injection. He describes the treatment honestly. He dislikes it, it changes your body, and there are days when it is genuinely hard. But he has found that resistance training, diet, mindset and refusing to make cancer the centre of his identity has made an enormous difference.  The episode also covers Will's decision to bank sperm before treatment, the five rounds of IVF he and his partner went through, and the arrival of their son Alfie in 2023. And then there is the Ironman: a 3.8km swim, a 180km ride and a 42km run, completed on ADT to raise funds for the Prostate Cancer Foundation of Australia, because sometimes the best answer to cancer is to go and do the hardest thing you can think of.  This is a conversation about prostate cancer, yes, but it is also about identity, resilience, fatherhood, fear, gratitude and what it really means to keep living.    Golden Tip: Prostate cancer is often entirely silent. Will had no urinary symptoms, no sexual dysfunction, nothing. His cancer was found in his bones first. Do not wait for a symptom to get a PSA test.     In This Episode, We Cover  Prostate cancer is often completely silent — screening matters even without symptoms  Why family history is a critical risk factor, and why sons and brothers of affected men should start screening from 40  The case for a national PSA screening program, and why early diagnosis changes outcomes  Long-term hormone therapy (ADT) causes fatigue, weight and body changes, and emotional shifts — resistance training is one of the most effective counter-measures  Exercise as medicine: how targeted resistance training can ease treatment side effects and may help slow disease progression  Fertility preservation and IVF are important conversations to have early in a cancer diagnosis, before treatment begins  Partners of cancer patients need their own support, not just a supporting role  Advanced or metastatic prostate cancer doesn't have to mean the end of an active, meaningful life    Key Message from Will  His message is simple. Do not let fear of what might happen stop you from living. You cannot control the buses. You can control what you do with the time you have.  Resources & Links  Will McDonald, PCFA ambassador https://www.pcfa.org.au/news-media/news/cancer-champion-takes-on-cairns-ironman-for-charity/   Book a telehealth consult with one of our sexual health nurse practitioners at Restorative Health Clinic  For more information check out our websites www.rshealth.com.au , www.makehardeasy.com.au and www.melissahadleybarrett.com  Prostate Cancer Foundation of Australia https://www.pcfa.org.au/  PCFA specialist prostate cancer nurses https://www.pcfa.org.au/support/prostate-cancer-specialist-nurses/    For more information visit our websites:  www.rshealth.com.au  www.makehardeasy.com.au  www.melissahadleybarrett.com    Need Support?  At Restorative Health Clinic, we support men and their partners with:  Penile rehabilitation after prostate cancer treatment  Erectile dysfunction  Vacuum pump and constriction ring education and prescription  Penile injection therapy  Intimacy and sexual recovery  Partner-inclusive support where appropriate  Practical, evidence-based strategies for rebuilding confidence and function    We offer telehealth consultations Australia-wide and internationally, making it easier for men to access experienced, compassionate support no matter where they live. If Steve's story sounds familiar, we would love to hear from you.    Restorative Health Clinic also has a psychologist-sexologist joining the team. If you are struggling with the emotional or psychological side of erectile dysfunction, prostate cancer recovery, or intimacy, we can support you there too – as an individual or as a couple.    Listen & Subscribe  If you found this episode helpful, please subscribe, rate, and review The Penis Project Podcast. Your feedback helps more men and their partners find these conversations. Search for The Penis Project Podcast on Spotify, Apple Podcasts, or your favourite podcast app.    We also have a free email list for updates, episodes, and resources. You can sign up via our website.     Connect With Us  We love hearing from real people navigating their health. If you would like to share your story or ask a question, get in touch.    Email: admin@rshealth.com.au    Websites:  rshealth.com.au   makehardeasy.com.au  melissahadleybarrett.com    Instagram:  @melissahadleybarrett  @restorativehealth.clinic    YouTube:  Melissa Hadley Barrett    TikTok:  @melissahadleybarrett    Facebook:  Melissa Hadley Barrett  Restorative Health Clinic    LinkedIn:  Melissa Hadley Barrett    TEDx Talk:  Watch on YouTube 

Becks Port, Chief People Officer at Okta, joined us on The Modern People Leader. We talked about why AI agents should be treated like digital coworkers, how Okta is thinking about agents on the org chart, and what the future of HR, career development, security, and team design could look like as humans work alongside machines.----  Sponsor Links:

Clare Bonham (Chief Product Officer) and Sébastien Baehni (CTO) from beqom joined us on The Modern People Leader. We talked about how managers can make better pay and performance decisions, why AI should support but not replace human judgment, and what intentional AI looks like in compensation.----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode326 Sponsor Links:

You probably have a pretty specific picture in your head when you hear the words “home break-in.” Maybe it involves someone kicking down the front door in the middle of the night. But according to our guest, that’s not usually how it works. And that might change the way you think about home security. In this episode of Grown-Up Stuff, Matt and Lea talk with Aaron Miller, Vice President at ADT and Head of ADT Blu, about the things that actually make your home vulnerable, from leaving obvious signs that no one’s home to relying on a camera notification without anyone there to respond. They also get into smart-home technology, DIY security systems, and the difference between simply knowing something is happening and actually having help when it does. And because life has a funny way of creating new reasons to think about security, like moving, having a baby, and going on vacation, Aaron shares some practical things you can do to protect your home without turning it into a fortress. Because being a grown-up means realizing that home security is probably one of those things you should think about before you need it. And, apparently, listening for someone breaking in at 2 a.m. isn't much of a strategy. This episode is sponsored by ADT.See omnystudio.com/listener for privacy information.

Heather Dunn, Chief People Officer at Brex, joined us on The Modern People Leader. We talked about Brex's rapid acquisition by Capital One and how Heather led through diligence, communication, and integration.----  Sponsor Links:

Patsy Mangan joined us on The Modern People Leader. We talked about Scribd Flex, why flexibility only works when it is paired with clarity and accountability, and why Scribd needed the GRIT Performance framework.----  Sponsor Links:

AUA2026: Advanced Prostate Cancer in the News 2026: A Case-Based Multidisciplinary Update CME Available: https://cme.auanet.org/URL/26DC010ONL LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral androgen blockers/inhibitors. Furthermore, to recognize high volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team. In addition, to recognize and employ molecular genetic testing to help dictate proper therapy. 2. Non Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): Diagnose M0CRPC and to be able to educate patients about using novel oral androgen receptor targeted agents added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three novel oral agents and to educate patients about side-effects and toxicities. Finally, to understand the pros and cons of PSMA PET scan imaging in further staging in this disease state. 3. Metastatic Castrate Resistant Prostate Cancer (M1 CRPC): Define and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and to be able to educate their patients on treatment options and be able to participate in a multidisciplinary team caring for men with this disease state of far advanced prostate cancer. 4. Identify that advanced prostate cancer is a complex group of disease states with an ever changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients. 5. Describe the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, Immune Checkpoint agents and novel AR targeted agents emerging in 2026 and beyond. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astellas Lantheus Medical Imaging Novartis Pharmaceuticals Corporation Pfizer, Inc

Brandon Roberts, leader of Talent Strategy and Workforce Transformation at ServiceNow, joined us on The Modern People Leader. We talked about how ServiceNow is redesigning HR for the AI era, why every role needs to be mapped for AI impact, and more.----  Sponsor Links:

Boards are making decisions about AI, transformation, succession, culture and growth. But how often does the person with the deepest understanding of the workforce have a seat at the table?In this episode of foHRsight, Naomi is joined by former CHROs Suzan Morno-Wade and Harriet Harty to explore why HR leaders remain significantly underrepresented on corporate boards, and why that gap matters more as organizations navigate increasingly complex workforce decisions. The conversation challenges some persistent assumptions about what CHROs bring to the boardroom. Strong HR leaders aren't simply experts in people programs. They understand organizational performance, leadership capability, succession, culture and enterprise risk. They know how to influence without owning the decision, ask discerning questions and connect talent decisions back to business strategy. And as AI reshapes work, that perspective becomes even more important. Technology decisions are also workforce decisions. Suzan and Harriet make the case for HR leaders to position those conversations in the language of strategy, risk, opportunity, financial analysis and measurable business outcomes. For CHROs who see board service in their future, there's also a practical message: don't wait until you leave the operating role to start preparing. Building board experience, relationships and a board-ready profile takes time. About Our guestsSuzan Morno-Wade is a former CHRO of Xerox whose career has spanned finance, human resources and enterprise leadership. Today, she advises organizations, serves on boards and supports greater representation in the C-suite and boardroom. Harriet Harty has held multiple executive HR roles, most recently serving as Chief Administrative Officer at ADT. She now works across advisory, board and executive coaching roles, bringing extensive experience in business transformation, talent and leadership. Stay Connected with foHRsightTo sign up for our monthly newsletter, foHRsight, click HERE Follow us on LinkedIn:Mark EdgarNaomi Titleman Collafuture foHRward Follow us on InstagramIf you are looking for more foHRsight, sign up for our monthly foHRsight newsletter. It's free and includes access to our quarterly white paper. This quarter's white paper is about Rethinking Entry-Level work in the Age of AI, produced with Dr. Miranda Rodak from Indiana University's Kelley school of business - an important topic for HR, Leadership and parents, students and society as a whole! https://www.futurefohrward.com/subscribeSupport the show

Jessica Zwaan joined us on The Modern People Leader. We talked about her first four months at Leapsome, why HR needs to operate more like a product team, and how AI agents, forward-deployed engineers, and flexible HR systems could reshape the future of people operations.----  Sponsor Links:

Molly Graham, Host of WorkLife Podcast & Co-Founder of Glue Club and The Guild, joined us on The Modern People Leader. We talked about career emergence, why fear is slowing down AI adoption at work, and why the future of HR will depend on leaders who can create clarity, curiosity, accountability, and better management habits for both people and AI agents.----  Sponsor Links:

Female Founders Series: When the EHR Goes Down: Building Real-Time Resilience Before the Next Outage Host: Janae Sharp Guests: Chao Cheng Shorland When the EHR goes down, care doesn't stop, but the chart, the meds, and the allergies do. Chao Cheng Shorland explains why EHR downtime is a patient safety problem, not just an IT one, and how her team is working to end pen-and-paper charting during outages. In this conversation: Why EHR downtime belongs under patient safety, and how mortality risk climbs when systems go dark The difference between continuity during failure and disaster recovery after failure How ransomware turned downtime from a two-hour event into a 24-day average What a lightweight downtime system needs to do: charting, orders, medications, ADT, and ED tracking with no user training How a passive, read-only system flips to active over HL7 and syncs back when the primary EHR returns Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Kate Connor, Chief Operating Officer at Moxie Communications Group, joined us on The Modern People Leader. We talked about how Moxie is adopting AI safely, why leaders should automate low-judgment work first, and how to embed AI into the culture without replacing human creativity, judgment, and relationships. ----  Sponsor Links:

Davida Lindsay-Bell, Chief People Officer at Hanna Andersson, joined us on The Modern People Leader. We talked about why AI transformation needs to start with people, how Hanna Andersson operationalized psychological safety, and why trust, learning, and intelligent failure are the foundation for lasting change.----  Sponsor Links:

Brian and Tom invite Neha Vapiwala, a Radiation Oncologist, to discuss areas of consensus and controversy from the PROTEUS trial of ADT +/- apalutamide in high-risk localized prostate cancer.

In this episode, UROONCO PCa chief editor Dr. Giancarlo Marra interviews Prof. Mary-Ellen Taplin from Dana–Farber Cancer Institute in the United States, on the results of the PROTEUS trial. The PROTEUS trial is a phase 3, double-blind, placebo-controlled trial evaluating the benefit of adding apalutamide to standard androgen deprivation therapy (ADT) in men with high-risk, localised prostate cancer undergoing radical prostatectomy.They discuss the rationale, patient selection and the results of this trial (dual primary endpoint), as well as the impact of the results on clinical practice. Prof. Taplin concludes in the take-home messages that this trial has illustrated the progress being made in regard to preventing and delaying relapse.To know more on this trial, read the abstract with expert commentary by UROONCO PCa associate editor Assoc. Prof. Pawel Rajwa. For more updates on prostate cancer, please visit our educational platform UROONCO PCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Laura Fuentes, CHRO at Hilton, joined us on The Modern People Leader. We talked about Hilton's hospitality mindset, why great leaders should operate like great hosts, and how Hilton scales culture, listening, recognition, and purpose across more than 500,000 team members.----  Sponsor Links:

AUA2026: Contemporary Management of Advanced Prostate Cancer: Guidelines and Beyond CME Available: https://cme.auanet.org/URL/26DC040ONL LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify appropriate use of genetic testing, genetic counseling as well as somatic testing. 2. Describe appropriate use of treatment-related to specific genetic alterations. 3. Identify appropriate combination therapy with ADT plus novel androgen receptor pathway inhibitors and chemotherapy. Early treatment intensification as well as appropriate de intensification will be discussed in mHSCPC. 4. Describe the treatments for non-metastatic CRPC and oncologic outcomes based on AUA/SUO and NCCN Guidelines. 5. Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO and NCCN Guidelines. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astellas Lantheus Medical Imaging Novartis Pharmaceuticals Corporation Pfizer, Inc

For decades, men with high-risk prostate cancer have routinely been told they need 18 to 36 months of androgen deprivation therapy (ADT) alongside radiation.But what if 12 months is enough?In this episode of the Dr. Geo Prostate Podcast, Dr. Geo Espinosa welcomes internationally recognized radiation oncologist Dr. Dan Spratt, Chair of Radiation Oncology at University Hospitals/Case Western Reserve University, to discuss groundbreaking research that could change how advanced prostate cancer is treated.Together they explore the latest MARCAP consortium data suggesting many men may receive the same cancer control with significantly less hormone therapy—potentially reducing years of unnecessary side effects while maintaining excellent outcomes. They also discuss how physicians personalize treatment decisions, the growing role of artificial intelligence with Artera AI, and why the future of prostate cancer treatment may involve doing less, not more.If you or someone you love is facing radiation therapy for prostate cancer, this episode provides one of the most important conversations happening in prostate cancer care today.What You'll Learn✔ Why 2-3 years of ADT may not be necessary for many patients✔ The new evidence supporting approximately 12 months of hormone therapy✔ Why longer hormone therapy can permanently affect testosterone recovery✔ How physicians balance cancer control with quality of life✔ The difference between NCCN guidelines and individualized patient care✔ Which patients may still benefit from longer hormone therapy✔ How AI (Artera AI) is helping personalize prostate cancer treatment✔ Why prostate cancer care is shifting toward treatment de-intensification✔ The future of precision medicine in radiation oncologyEpisode Timestamps00:00 Introduction01:30 Meet Dr Dan Spratt02:22 Why ADT Lasts Years05:42 How ADT Helps Radiation08:49 Personalizing ADT Duration12:39 Guidelines and Real World Use18:03 Who Needs Long Term ADT21:13 Artera AI Explained23:19 Old Data and Modern Outcomes27:28 De Intensification Future31:33 Biomarkers for Urologists33:57 Choosing Artera vs Decipher37:28 Final Takeaways and OutroKey Discussion PointsNew MARCAP consortium analysis on ADT durationRadiation sensitivity and androgen deprivationWhy many men never fully recover testosterone after prolonged ADTBalancing survival outcomes with quality of lifeShared decision-making between physician and patientGenomic classifiers including DecipherAI biomarkers and Artera AIPersonalized radiation oncologyModern imaging and PSMA PETDe-intensifying prostate cancer treatmentPrecision medicine in localized prostate cancerThe future of individualized prostate cancer careResources Mentioned• MARCAP Consortium research on androgen deprivation therapy duration• NCCN Prostate Cancer Guidelines (discussed throughout the episode)• Artera AI clinical decision support platform (discussion)• Decipher genomic classifier• PSMA PET imaging• MRI-guided prostate cancer staging___________________________________

Jessie Zwaan, author of Purpose and Work and Built for People, joined us on The Modern People Leader. We talked about why the old purpose-at-work narrative is breaking, how people relate to work through jobs, careers, and callings, and why HR leaders need to rethink how they build meaning into work.----  Sponsor Links:

We've been told for decades that giving testosterone to a man with prostate cancer is like throwing gasoline on a fire. But what if, in the right context, it actually acts as the extinguisher?” It sounds like medical heresy, yet this is the foundation of Bipolar Androgen Therapy (BAT). Imagine a treatment that intentionally cycles your hormones from extreme highs to extreme lows to "overload" cancer cells and reset their sensitivity to medicine.In this episode, we sit down with a true pioneer of this paradigm shift: Dr. Michael Schweizer. An Associate Professor at the Fred Hutchinson Cancer Center and a key architect behind the original BAT trials at Johns Hopkins, Dr. Schweizer is the scientist moving the bar for men with advanced, castrate-resistant disease. We're moving past the fear-based dogma to look at the clinical data that proves supraphysiologic testosterone isn't just a quality-of-life booster—it's a sophisticated weapon against resistant tumors.In this episode, you'll learn:The "Hormone Shock" Mechanism: How flooding the body with 1,500+ ng/dL of testosterone causes "mitotic catastrophe" in cancer cells adapted to low-androgen environments.The Resensitization Secret: Why cycling BAT can actually "reset" your cancer, making drugs like Enzalutamide work again after they've failed.Precision Selection: Which specific genetic mutations (like TP53) might predict who becomes an "exceptional responder" to high-dose testosterone.The Sequential Strategy: Why the order of your treatments—BAT first, then RPIs—could potentially extend survival by nearly 10 months.⏱️ Chapters00:00 Introduction: Can Testosterone Treat Prostate Cancer? 02:00 The surprising origin of Bipolar Androgen Therapy (BAT) 04:10 ⭐ Stop & Watch: Why Charles Huggins hinted at this decades ago 07:10 Why ordinary testosterone therapy failed—and BAT didn't 08:20 ⭐ Stop & Watch: The BAT protocol explained (400 mg every 28 days) 10:00 Why BAT is only used in castration-resistant prostate cancer 14:05 ⭐ Stop & Watch: The TRANSFORMER trial—did BAT actually work? 16:20 ⭐ Stop & Watch: How BAT may make failed treatments work again 20:30 ⭐ Stop & Watch: If testosterone isn't the enemy...why do we suppress it? 22:10 ⭐ Must Watch: The biology that completely changes how we think about testosterone 24:10 How BAT damages cancer DNA 26:30 BAT, quality of life, and survival—what the evidence really shows 30:00 ⭐ Stop & Watch: The sequencing strategy that could add months of cancer control 31:30 Which patients may respond best to BAT? 33:20 ⭐ Must Watch: Why every advanced prostate cancer patient should consider genetic testing 36:00 Can someone on ADT simply start testosterone? 40:00 Where BAT fits among today's prostate cancer treatments 43:00 ⭐ Stop & Watch: BAT + Lutetium PSMA—the next frontier 45:00 How to find BAT clinical trials 47:00 Should hormone therapy ever be stopped? 53:00 Final thoughts____________________________________

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-power-of-timing-therapies-that-change-outcomes/57193/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/precision-in-practicebringing-targeted-therapy-to-mhspc/57201/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Daniel Bay, Chief People Officer at Underdog, joined us on The Modern People Leader. We talked about why HR teams in hypergrowth should stop copying big-company playbooks, how Underdog invests deeply in manager coaching, and why impact matters more than activity.----  Sponsor Links:

AUA2026: Focus on: ADT in the Modern Era - Balancing Cancer Control and Cardiovascular Safety CME Available: https://cme.auanet.org/URL/FOCUS265ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Integrate cardiovascular (CV) risk assessment into ADT initiation by applying key findings from the REVELUTION-1 trial to identify patients at elevated risk for atherosclerosis and MACE. 2. Compare and apply the CV safety profiles of LHRH agonists versus GnRH receptor antagonists to guide personalized ADT selection in patients with varying CV risk. 3. Implement streamlined monitoring strategies for men on oral ADT, including testosterone levels, lipid and blood pressure evaluation, and surveillance for early CV risk indicators. 4. Collaborate with cardiology and primary care to optimize statin use and coordinate CV risk-reduction strategies for prostate cancer patients receiving ADT. 5. Strengthen shared decision making and adherence by incorporating discussions of oncologic benefit, CV risk, and mitigation strategies into routine oral ADT counseling and follow-up. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Pfizer, Inc Sumitomo Pharma America, Inc.

In this episode of The Dr. Haley Show, Dr. Michael Haley speaks with Michael Bovarnick, founder of The Prostate Education Project, about his personal journey through prostate cancer, recurrence, treatment decisions, and the mission that grew out of his experience.Michael shares what it was like to hear the words “you have prostate cancer,” why education became such an important part of his journey, and how clear information can help reduce fear for men, spouses, caregivers, and families facing prostate cancer.The conversation covers PSA testing, Gleason scores, prostate cancer recurrence after prostate removal, androgen deprivation therapy (ADT), ADT side effects, ADT holidays, intimacy and relationship challenges, and the importance of having a spouse, partner, or loved one present during medical appointments.Dr. Haley and Michael also discuss Michael's long history with Haley Nutrition's Aloe Vera Gel Health Drink as part of his personal wellness routine. Aloe vera is not presented as a cancer cure. Instead, this conversation focuses on education, supportive wellness, patient empowerment, and asking better questions when navigating serious health decisions.Michael's closing message is simple and powerful:Knowledge reduces fear.Understanding builds confidence.Education empowers patients.Episode Resources:The Prostate Education Projecthttps://theprostateeducationproject.org/Haley Nutrition Aloe Vera Gel Health Drinkhttps://haleynutrition.com/Dr. Haley Show Noteshttps://drhaley.com/Haley Nutritionhttps://haleynutrition.com/Episode Highlights:00:00 PSA testing and false positives00:39 Meet Michael Bovarnick of The Prostate Education Project02:50 How Dr. Haley and Michael first connected03:14 Michael's prostate cancer diagnosis and aloe vera story05:37 Important disclaimer about aloe vera and cancer08:05 Why prostate cancer can return after prostate removal10:54 Life today after prostate cancer recurrence12:18 Prostate cancer awareness and rising diagnosis rates13:36 PSA testing, screening, and Dr. Haley's personal story16:59 Hearing the words “you have prostate cancer”18:46 Intimacy, relationships, and emotional challenges23:10 What doctors explain — and what patients may miss26:22 Advice for newly diagnosed men in the panic phase28:33 PSA, Gleason score, and treatment decisions31:06 What is ADT? Androgen deprivation therapy explained32:45 ADT side effects doctors may not fully prepare you for34:51 Why you should bring a partner to appointments36:39 What is an ADT holiday?39:27 PSA testing advice for men over 4040:36 Urinary symptoms, enlarged prostate, and getting checked42:49 Prostate cancer symptoms beyond urinary problems43:52 Exercise, diet, bone health, and muscle health during ADT45:00 Exploring TheProstateEducationProject.org46:47 Spanish-language resources and community outreach48:32 Final thoughts: Knowledge reduces fearMedical Disclaimer:This podcast is for educational purposes only and is not medical advice. The information shared in this episode should not be used to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider regarding PSA testing, prostate cancer screening, diagnosis, medications, supplements, treatment options, or any health-related decisions.Aloe vera is discussed in this episode as part of Michael Bovarnick's personal wellness routine and experience. It is not presented as a treatment or cure for prostate cancer.About Michael Bovarnick:Michael Bovarnick is the founder of The Prostate Education Project, a growing educational resource created to help prostate cancer patients, spouses, caregivers, and families better understand the prostate cancer journey. His work focuses on clear explanations, practical tools, lived experience, and helping people know what questions to ask when facing diagnosis, treatment decisions, side effects, recurrence, and recovery.About Dr. Michael Haley:Dr. Michael Haley is the host of The Dr. Haley Show and founder of Haley Nutrition, known for producing raw, inner-leaf Aloe Vera Gel Health Drink and other natural wellness products. Through the podcast, Dr. Haley explores natural health, patient education, practical wellness strategies, and conversations that help listeners take a more informed role in their health journey.

Nichole Viviani, Chief People, Culture and Change Officer at Global Payments, joined us on The Modern People Leader. We talked about why culture makes or breaks M&A, how Global Payments aligned 27,000 people through “goals before roles,” and why leaders need to over-communicate through uncertainty.----  Sponsor Links:

Courtney Kolar, Chief People Officer at Neighborly, joined us on The Modern People Leader. We talked about how she helped build an HR function from a three-person team into a 40-person people organization, the People Services 2020 roadmap that created the foundation for scale, and why every company should operate as if it needs to be IPO ready.----  Sponsor Links:

Sunaina Lobo, Chief People Officer at Omnissa, joined us on The Modern People Leader. We talked about why the HR-IT partnership is becoming critical in the AI era, how Omnissa is approaching AI transformation with a small but mighty team, and what it takes to build an AI-first culture while maintaining trust and engagement.----  Sponsor Links:

Featuring a slide presentation and related discussion from Dr Rana R McKay, including the following topics: Overview of the current landscape of prostate cancer (0:00) Mechanism of action of androgen deprivation therapy (ADT) (3:51) Findings from the Phase III HERO study evaluating relugolix versus leuprolide for advanced prostate cancer (7:18) Real-world evidence regarding the use of relugolix (12:27) Adverse event profile associated with ADT (18:34) Case: A man in his early 70s with metastatic hormone-sensitive prostate cancer who receives ADT at various timepoints of treatment and is currently on relugolix (21:46) Case: A man in his early 60s with high-risk locally advanced prostate cancer who receives various androgen receptor pathway inhibitors in addition to relugolix (28:06) CME information and select publications

Patricia Frost, Chief People and Places Officer at Seagate, joined us on The Modern People Leader. We talked about her military-to-CPO journey, how Seagate built Talent Link to unlock internal mobility, and what it looks like to democratize AI across a global workforce.----  Sponsor Links:

Kate Railton, Chief People Officer at Mejuri, joined us on The Modern People Leader. We talked about how Mejuri transitioned from e-commerce into retail, why they've decided to flatten the organization, and the business review cadences and operating model that allow them to move faster.----  Sponsor Links:

Still using androgen deprivation therapy (ADT) alone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)? Learn the latest on optimizing outcomes with combination therapies. Credit available for this activity expires: 6/25/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/new-era-mhspc-treatment-evaluating-emerging-doublet-and-2026a1000kt7?ecd=bdc_podcast_libsyn_mscpedu

Daniel moderated a live panel at Running Remote 2026 with Carmen Amara (Yelp), Brandon Sammut (Zapier), and Vinícius Coelho (Time Doctor) to discuss how AI is reshaping leadership, management, and career growth. ----  Sponsor Links:

In this compelling episode of the Dr. Geo Prostate Podcast, Dr. Geo sits down with internationally renowned exercise oncology pioneer Professor Robert Newton to explore the groundbreaking science behind exercise as medicine for cancer.Inspired by his father's battle with prostate cancer, Professor Newton has spent decades researching how targeted exercise can improve treatment outcomes, preserve muscle mass, strengthen immune function, reduce treatment side effects, and potentially slow cancer progression. Together, Dr. Geo and Professor Newton discuss why muscle is far more than a movement organ—it functions as a powerful endocrine organ that releases cancer-fighting compounds known as myokines.The conversation dives deep into exercise intensity, resistance training, chemotherapy and radiation timing, wearable technology, exercise "dosing," and the landmark Phase III clinical trial that demonstrated exercise can significantly improve survival outcomes in cancer patients. They also discuss practical strategies for overcoming fear of the gym, maintaining muscle during androgen deprivation therapy (ADT), and why sitting all day may undermine your health even if you exercise regularly.Whether you're living with prostate cancer, supporting a loved one, or simply interested in maximizing your healthspan, this episode provides actionable, science-backed strategies to help you move from surviving to thrivingEpisode Timestamps00:00 Introduction & Guest Welcome 03:00 Rob Newton's Father & Origin Story 09:30 Exercise as the #1 Anti-Cancer Tool 17:00 Landmark Exercise Oncology Trial 20:00 Exercise as Medicine 26:00 Resistance Training Intensity Explained 35:30 Exercise Before Radiation & Chemotherapy 40:00 Exercise Timing Around Treatment 47:00 Myokines: Muscle as Medicine 52:00 NEAT & Daily Movement 58:00 Final Takeaways & Closing ThoughtsResources MentionedMy Exercise Medicine for Cancer by Professor Robert NewtonExercise Medicine Research InstituteNew England Journal of Medicine Exercise Oncology TrialAmerican Society of Clinical Oncology (ASCO) Researc___________________________________

Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast.   In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent FDA approvals in the GU space: PROTEUS:  trial comparing ADT monotherapy to apalutamide plus ADT in high-risk localized prostate cancer. We explored its findings, implications, and the ongoing debate surrounding its control arm. TALAPRO-3 Study: impact of PARP inhibitors combined with enzalutamide in metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) mutations. We discussed the nuances of HRR mutations and their clinical significance. CAPITELLO-281: insights into the recent approval of this AKT inhibitor for metastatic castration-sensitive prostate cancer with PTEN loss, based on the CAPItello-281 study. EV-302 update: combination of EV-pembrolizumab still maintains the doubling of survival benefit with longterm follow up. POTOMAC: durvalumab + BCG induction therapy for high-risk non-muscle invasive bladder cancer (NMIBC) could be a choice for a selected patient population. LITESPARK-022: The new approval of belzutifan with pembrolizumab in the adjuvant setting, discussing its efficacy and the importance of patient selection.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o ' Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Throughout the episode, we emphasized the importance of balancing treatment benefits with potential adverse events, as well as the need for shared decision-making in clinical practice. #GUOncology, #ASCO2026, #ProstateCancer, #BladderCancer, #RenalCellCarcinoma, #OncologyBrothers

Ray'n Terry, Chief People Officer at MOO, joined us on The Modern People Leader to discuss why AI should create more space for humanity at work instead of simply increasing productivity. We talked about balancing business performance with employee wellbeing, rethinking performance management in an AI-powered world, and why leaders must intentionally help people reclaim time, creativity, and connection.----  Sponsor Links:

Amy Reichanadter, Chief People Officer at Databricks, joined us on The Modern People Leader to discuss her upskilling journey throughout her career, creating consumer-grade employee experiences, and leading through rapid technological change. ----  Sponsor Links:

Dennis Rader was the council president of Christ Lutheran Church in Park City, Kansas, on the morning of February 25, 2005. The Wichita Police Department was, at the same moment, on its way to arrest him. The thing that had identified him as BTK was a metadata trace from a Microsoft Word document he had saved to a church computer in his role as council president.He had volunteered for the council. He had volunteered to print agendas. He had risen through the ranks to council president, the visible layperson at a small congregation. He had been doing both jobs for years. The killing and the church. The Cub Scout pack and the typed letters to the press. The compliance officer truck and the kits in the garage.In the third chapter of host Tony Brueski's five-part Hidden Killers investigation, every official role Dennis Rader chose for himself gets examined for what it actually gave him. The ADT alarm installer job that put him inside hundreds of Wichita homes legally during the most active years of his killing. The Cub Scout pack leader role that put him in front of children while teaching them the family of knots that had been showing up at his crime scenes since 1974. The Lutheran council seat that gave him community standing and, eventually, identified him to investigators. The Sedgwick County Zoning Appeals seat. The Animal Control Advisory Board. The compliance officer truck.This episode also walks through Misty King's story. A Park City divorcee who fled the state with her two children after Dennis Rader, in his city role, made her life unlivable.This is the third uncomfortable truth of the series. Dennis Rader did not hide despite his costumes. He hid inside them.END LINKSJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1 Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/TrueCrimePodDISCLAIMERThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.HASHTAGS#BTK #DennisRader #ChristLutheran #ChurchCouncil #HiddenKillers #TrueCrime #SerialKillers #ParkCity #ColdCase #UncomfortableTruths

Cameron Price, Head of People & Talent at Medium, joined us on The Modern People Leader to discuss how people teams can lead AI change management through trust, curiosity, and human-centered design. We talked about AI fluency, balancing innovation with authenticity, measuring employee sentiment around AI adoption, and why humans-first leadership matters more than ever. ----  Sponsor Links:

For half a century, the BTK Killer story has been told the way Dennis Rader wanted it told. Factor X. The Minotaur. The BTK brand. Every term that has anchored his mythology came from a typewriter in his own kitchen in Park City, Kansas. Every term was his.In this first chapter of a five-part investigation from True Crime Today, host Tony Brueski sets the version of Dennis Rader that documentaries have repeated for forty-seven years next to the actual investigative file. The two don't match.The man who wrote the 1978 Factor X letter to KAKE-TV was a thirty-two-year-old husband and father. An alarm installer for ADT in Wichita. A student at Wichita State University working toward a degree in the administration of justice. He had taken courses on profiling. He knew what serial killers were supposed to sound like in the cultural imagination of the late seventies. He typed himself into the role.The press printed his words. The cops filed his words. The country read his words. And for nearly fifty years, when somebody has tried to explain Dennis Rader, they have explained him the way he wanted to be explained.This episode walks through the 1978 letter sentence by sentence. The literary references he borrowed from. The cultural figures he compared himself to. The contradictions inside the letter that read, in retrospect, less like the confession of a possessed killer and more like the audition tape of a man trying out for a role.The series will continue with the chase that didn't close, the official roles that made him invisible, the thirteen-year silence between his confirmed killings, and the floppy disk that ended his thirty-one years of getting away with it. Start here.END LINKSJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1 Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/TrueCrimePodDISCLAIMERThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.HASHTAGS#BTK #DennisRader #BTKKiller #TrueCrimeToday #FactorX #SerialKillers #Wichita #ParkCity #TrueCrime #ColdCase

Nir Leibovich, Product Executive at QuickBooks Workforce, joined us on The Modern People Leader to discuss why HR and finance teams struggle when data lives in silos and how unified systems create better business decisions. Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode306----  Sponsor Links:

Amy Schwartz, Chief People Officer at Wiz, joined us on The Modern People Leader. We talked about why HR alone can't create a high-performance culture, why relationships and influence matter more than HR systems, and why "picking up the trash" - a leadership philosophy she picked up working in casinos - has stuck with her ever since.----  Sponsor Links:

In this episode, Andrew is joined by Jimmy Lin from ADT who shares the insider story behind ADT's new DIY-focused Blu system—an easy-to-install, smart security kit designed for the modern homeowner. We break down how ADT may leverage open standards like Matter and Z-Wave, aiming to unify the smart home ecosystem and finally bridge the gap between security and automation.You'll uncover:How ADT's innovative products like the new Live Light smart sign and color night-vision cameras empower homeowners to be proactive rather than reactive.The role of AI and sensor fusion, like Wi-Fi and activity zone detection, in predicting threats before they happen.Why a focus on privacy, seamless integration, and ease of use is transforming the DIY security market.The strategic move into open protocols to create a more connected, interoperable smart home landscape.What's next for ADT: The possibility of introducing scene automation, smart home triggers, and voice command support like Siri shortcuts to truly integrate security with daily life.Jimmy Lin is VP of Product Management at ADT, steering innovations that bridge the gap between trusted home security and intelligent automation. With extensive experience in consumer electronics and AI-powered products—from GoPro cameras to AR glasses—Jimmy brings a keen eye for transforming classic brands into future-ready powerhouses.This episode is packed with actionable insights and future trends that will shape your smart home strategy. Perfect for tech lovers, security pros, and anyone eager to stay ahead of the curve. Don't miss out—hit play now and discover how ADT is redefining what home security can be.Send me your smart home questions and recommendations with the hashtag #SmartHomeInsider. Tweet and follow your host at:@andrew_osu on Twitter@andrewohara941 on ThreadsEmail me hereSponsored by:Shopify: Sign up for a one-dollar-per-month trial period at shopify.com/homekit!Copilot Money:  Limited-time: Get two months free when you sign up at copilot.money/smarthome and use coupon code SMARTHOME!Smart Home Insider YouTube ChannelSubscribe to the Smart Home Insider YouTube Channel and watch our episodes every week! Click here to subscribe.Links from the showGovee TV Backlight 3Govee G25 Filament BulbBose Lifestyle LineupBlu by ADTThose interested in sponsoring the show can reach out to us at: andrew@appleinsider.com